Eli Lilly announced a $3 billion investment to expand oral solid-dose manufacturing in China to support upcoming launches, including its obesity candidate orforglipron, and pledged $500 million to boost South Korea’s biomedical sector. The moves follow broader pharma investment trends in Asia and align manufacturing capacity with regional launch plans and supply-chain resilience. Lilly framed the China expansion as a decade-long manufacturing commitment to secure launch supply and reduce lead times for regional markets. The South Korea pledge accompanies government-level talks and is aimed at strengthening local R&D and clinical trial capacity. For manufacturers, onshoring or regionalizing production for high-demand metabolic medicines is a strategic response to scaling pressures and geopolitical supply risk.